In conclusion, we demonstrated for the first time that low NCX1 enhances the anti-MM activity of BTZ both in vitro and in vivo, which provided a new marker to overcome BTZ resistance and improve MM patient prognosis and survival. The gene discussed is CASC3; the disease is Miyoshi myopathy.